

**Australian Securities Exchange Limited
Companies Announcements Office
SYDNEY**

23 March, 2012

Completion of Takeover Offers and Commencement of Compulsory Acquisition


Probiomics Limited (ASX: PCC) (**Probiomics**) is pleased to announce that the takeover offers made by Probiomics for all the shares, options and tranche 1 convertible note interests in Hunter Immunology Limited (**Takeover Offers**) under its Bidder's Statement dated 13 December, 2011 closed at 5.00 p.m. (AEDST) on Friday 23 March, 2012, with Probiomics having acquired an aggregate relevant interest in:

- (a) 95.98% (by number) of all Hunter shares;
- (b) 96.17% (by number) of all Hunter options; and
- (c) 100% (by number) of all Hunter tranche 1 convertible note interests.

The market is advised that:

- (1) as at the close of the Takeover Offers (being 5.00 p.m. (AEDST) on Friday 23 March, 2012), each of the defeating conditions to the Takeover Offers had been satisfied or waived; and
- (2) Probiomics has today commenced compulsory acquisition for all remaining Hunter shares and options that are not the subject of an acceptance of the Takeover Offers, pursuant to section 661A of the *Corporations Act 2001* (Cth).

Yours sincerely



Patrick Ford
Non Executive Chairman

About Probiomics Limited

Probiomics has proprietary ownership of a unique probiotic strain – PCC®

PCC® has been clinically proved to have superior qualities to other probiotic strains – particularly in promoting systemic immune response.

Probiomics' commercial objective is to earn royalties from licensing PCC® to distribution companies selling products in global markets.

CONTACTS

Mr Ashok Jairath - Chief Financial Officer and Company Secretary

Tel: 02 9844 5422

Email ashok.jairath@probiomics.com.au